MultiplAI leverages genomics and AI to provide universal remote screening for cardiovascular diseases among other complex diseases. We use a liquid biopsy of whole blood based on RNA sequencing and deep learning looking at all biomarkers in the blood, thus creating a superb biomarker to detect diseases earlier. Our test can be used in continuous testing both for preventative screening and post-treatment monitoring. Given that it requires only a simple blood sample, it can be administered remotely, anywhere, and costs a fraction of existing diagnostic methods.
MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing, and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.
B2B
1 to 25
Seed
N/A
Scaling Up
2019
Healthcare
Health Care Facilities & Hospitals
Biotechnology
N/A
Increase Efficiency
Service
Yes
Active
Machine Learning
N/A
Software
N/A
0
1
$2.7M
Company was founded 2019 and it took almost 4 years (Mar 2023) to raise first external round
Investors
Interested in researching MultiplAI Health?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about MultiplAI Health
Potential Customers
Interested in what they do or partnership?
Learn more about how they work